Mortalität unter Piperacillin-Tazobactam Therapie mit Piperacillin-Tazobactam: Zeit für eine kritische Neubewertung? Mortality of patients with sepsis administered Piperacillin-Tazobactam vs Cefepime. Chanderraj R, Admon AJ, He Y, Nuppnau M, Albin OR,...
More
Mortalität unter Piperacillin-Tazobactam Therapie mit Piperacillin-Tazobactam: Zeit für eine kritische Neubewertung? Mortality of patients with sepsis administered Piperacillin-Tazobactam vs Cefepime. Chanderraj R, Admon AJ, He Y, Nuppnau M, Albin OR, Prescott HC, Dickson RP, Sjoding MW JAMA Intern Med 2024; 184:769-777 IMPORTANCE: Experimental and observational studies have sug- was 90-day mortality. Secondary outcomes included organ failure- gested that empirical treatment for bacterial sepsis with antianaero- free, ventilator-free, and vasopressor-free days. The 15-month piper- bic antibiotics (eg, piperacillin-tazobactam) is associated with adverse acillin-tazobactam shortage period was used as an instrumental vari- outcomes compared with anaerobe-sparing antibiotics (eg, cefepime). able for unmeasured confounding in antibiotic selection. However, a recent pragmatic clinical trial of piperacillin-tazobactam RESULTS: Among 7569 patients (4174 men [55%]; median age, and cefepime show
Less
